Clinical Aspects of Alzheimer's Disease

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Second Edition

Volumn , Issue , 2011, Pages 37-50

  Knopman, David ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Dementia; Epidemiology; Mild cognitive impairment; Natural history; Risk factors

Indexed keywords

EID: 84886052415     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341256.ch8     Document Type: Chapter

References (90)

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's & Dementia: Journal of the Alzheimer's Association 2011; 7.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association, 1994.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
4. Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42: 115-119.
5. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer 's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262: 2551-2556.
6. Graves AB, Larson EB, Edland SD, et al. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state. The Kame Project. Am J Epidemiol 1996; 144: 760-771.
7. Hendrie HC, Osuntokun BO, Hall KS, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 1995; 152: 1485-1492.
8. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154.
9. Kokmen E, Beard CM, Offord KP, Kurland LT. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology 1989; 39: 773-776.
10. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995; 310: 970-973.
11. Pfeffer RI, AfifiAA, Chance JM. Prevalence of Alzheimer's disease in a retirement community. Am J Epidemiol 1987; 125: 420-436.
12. White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging Study. JAMA 1996; 276: 955-960.
13. Fillenbaum GG, Heyman A, Huber MS, et al. The prevalence and 3-year incidence of dementia in older Black and White community residents. J Clin Epidemiol 1998; 51: 587-595.
14. Canadian Study of Health and Aging Working Group. Canadian Study f Health and Aging: study methods and prevalence of dementia. CMAJ 1994; 150: 899-913.
15. Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000; 55: 198-204.
16. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998; 55: 809-815.
17. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998; 51: 728-733.
18. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 1993; 43: 515-519.
19. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995; 273: 1354-1359.
20. Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 1998; 147: 574-580.
21. Rocca WA, Cha RH, Waring SC, Kokmen E. Incidence of dementia and Alzheimer's disease: a reanalysis of data from Rochester, Minnesota, 1975-1984. Am J Epidemiol 1998; 148: 51-62.
22. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994; 271: 1004-1010.
23. Larson EB, Reifler BV, Sumi SM, Canfield CG, Chinn NM. Diagnostic evaluation of 200 elderly outpatients with suspected dementia. J Gerontol 1985; 40: 536-543.
24. Thal LJ, Grundman M, Klauber MR. Dementia: characteristics of a referral population and factors associated with progression. Neurology 1988; 38: 1083-1090.
25. Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 1996; 46: 641-650.
26. Ahlskog JE, Waring SC, Kurland LT, et al. Guamanian neurodegenerative disease: investigation of the calcium metabolism/heavy metal hypothesis. Neurology 1995; 45: 1340-1344.
27. McGeer PL, Schwab C, McGeer EG, Haddock RL, Steele JC. Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Neurology 1997; 49: 400-409.
28. Waring SC, O'Brien PC, Kurland LT, et al. Apolipoprotein E allele in Chamorros with amyotrophic lateral sclerosis/parkinsonism-dementia complex. Lancet 1994; 343: 611.
29. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998; 279: 751-755.
30. Zhang MY, Katzman R, Salmon D, et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990; 27: 428-437.
31. Folstein MF, Bassett SS, Anthony JC, Romanoski AJ, Nestadt GR. Dementia: case ascertainment in a community survey. J Gerontol 1991; 46: M132-138.
32. Schoenberg BS, Anderson DW, Haerer AF. Severe dementia. Prevalence and clinical features in a biracial US population. Arch Neurol 1985; 42: 740-743.
33. Stern Y, Tang MX, Denaro J, Mayeux R. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann Neurol 1995; 37: 590-595.
34. Whalley LJ, Starr JM, Athawes R, Hunter D, Pattie A, Deary IJ. Childhood mental ability and dementia. Neurology 2000; 55: 1455-1459.
35. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 1996; 275: 528-532.
36. McGurn B, Deary IJ, Starr JM. Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia. Neurology 2008; 71: 1051-1056.
37. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666.
38. Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004; 63: 228-233.
39. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-281.
40. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451.
41. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483.
42. Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997; 278: 136-140.
43. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-1075.
44. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004; 63: 1168-1174.
45. Giannakopoulos P, Gold G, Duc M, Michel JP, Hof PR, Bouras C. Neuroanatomic correlates of visual agnosia in Alzheimer's disease: a clinicopathologic study. Neurology 1999; 52: 71-77.
46. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55: 335-346.
47. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Neurology 2001; 56: 1143-1153.
48. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007; 62: 406-413.
49. Huff FJ, Growdon JH, Corkin S, Rosen TJ. Age at onset and rate of progression of Alzheimer's disease. J Am Geriatr Soc 1987; 35: 27-30.
50. Jacobs D, Sano M, Marder K, et al. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994; 44: 1215-1220.
51. Wilson RS, Beckett LA, Bennett DA, Albert MS, Evans DA. Change in cognitive function in older persons from a community population: relation to age and Alzheimer disease. Arch Neurol 1999; 56: 1274-1279.
52. Smith GE, Kokmen E, O'Brien PC. Risk factors for nursing home placement in a population-based dementia cohort J Am Geriatr Soc 2000; 48: 519-525.
53. Schneider LS. Tracking dementia by the IMC and the MMSE. J Am Geriatr Soc 1992; 40: 537-538.
54. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer 's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-396.
55. Morris JC, Edland S, Clark C, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993; 43: 2457-2465.
56. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI: Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995; 45: 1451-1455.
57. Heyman A, Peterson B, Fillenbaum G, Pieper C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology 1996; 46: 656-60.
58. Tierney MC, Szalai JP, Snow WG, Fisher RH. The prediction of Alzheimer disease. The role of patient and informant perceptions of cognitive deficits. Arch Neurol 1996; 53: 423-427.
59. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994; 44: 1427-1432.
60. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274-1278.
61. Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer 's disease. Neurology 1995; 45: 957-962.
62. Howieson DB, Dame A, Camicioli R, Sexton G, Payami H, Kaye JA. Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. J Am Geriatr Soc 1997; 45: 584-589.
63. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham cohort. Arch Neurol 2000; 57: 808-813.
64. Blacker D, Lee H, Muzikansky A, et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 2007; 64: 862-71.
65. Smith CD, Chebrolu H, Wekstein DR, et al. Brain structural alterations before mild cognitive impairment. Neurology 2007; 68: 1268-1273.
66. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-758.
67. Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of agerelated memory decline and the APOE epsilon4 effect. N Engl J Med 2009; 361: 255-263.
68. Sperling RA, Aisen P, Beckett L, et al. Towards defining the preclinical stage of Alzheimer's Disease: Recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimer's & Dementia: Journal of the Alzheimer's Association 2011; 7.
69. Albert M, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Report of the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimer's & Dementia: Journal of the Alzheimer's Association 2011; 7.
70. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
71. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397-1403.
72. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 2002; 72: 491-497.
73. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
74. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
75. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2009; Aug 4 (epub ahead of print).
76. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-568.
77. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
78. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786-794.
79. Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 1993; 50: 949-954.
80. McDonald CR, McEvoy LK, Gharapetian L, et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 2009; 73: 457-465.
81. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009; 72: 1048-55.
82. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69: 871-877.
83. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
84. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338: 506-511.
85. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388.
86. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
87. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
88. Costa PTJ, Williams TF, Somerfield M. Early Identification of Alzheimer 's Disease and Related Dementias. Clinical Practice Guideline Vol. 19. Washington DC: US Dept of Health and Human Services, Agency for Health Care Policy and Research, 1996.
89. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
90. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter for diagnosis and evaluation of dementia (summary statement). Neurology 1994; 44: 2203-2206.